Stocks and Investing
Stocks and Investing
Tue, August 11, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, August 10, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tyler Van Buren Maintained (TBPH) at Buy with Decreased Target to $30 on, Aug 10th, 2020
Tyler Van Buren of Piper Sandler, Maintained "Theravance Biopharma, Inc." (TBPH) at Buy with Decreased Target from $35 to $30 on, Aug 10th, 2020.
Tyler has made no other calls on TBPH in the last 4 months.
There are 2 other peers that have a rating on TBPH. Out of the 2 peers that are also analyzing TBPH, 0 agree with Tyler's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Tyler
- Anupam Rama of "JP Morgan" Initiated at Buy and Held Target at $29 on, Tuesday, July 7th, 2020
- Marc Frahm of "Cowen & Co." Initiated at Buy and Held Target at $42 on, Wednesday, May 13th, 2020